Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose ADME and pharmacokinetics study of [14C]JDQ443 in healthy male participants
NL-OMON51491Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of opnurasib in cancer, sponsored by Novartis. Primary endpoints: Rates and routes of excretion of total radioactivity, Pharmacokinetics of total radioactivity in whole blood and plasma and 1 more. Started Dec 2021; status: active, not recruiting.
02
Drugs
opnurasib
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON51491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51491.